

# Leishmaniasis country profile — 2016

(Published March 2019)



## Israel

### COUNTRY GENERAL INFORMATION (World Bank, 2016)

Total population:	8,547,100
Gender F / M (%):	50.4 / 49.6
Population, age group <15/ ≥15 years (%):	28 / 72
Life expectancy at birth (F/M, years) (2015):	84.1 / 80.3
GDP (PPP int \$):	37,783
Income status:	High
Number of 1 <sup>st</sup> sub-national administrative level divisions, name:	7 Mahoz (District)

### EPIDEMIOLOGY

	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Endemic	Non endemic	Non endemic
Number of new cases (incidence):	1	240	N/A	N/A
Number of relapses <sup>1</sup> :	No data	No data	N/A	N/A
<b>Total number of cases:</b>	<b>1</b>	<b>240</b>	<b>N/A</b>	<b>N/A</b>
Imported cases (#, %):	0, 0%	0, 0%	N/A	N/A
Gender distribution (% F):	0%	33%	N/A	N/A
Age group distribution (% < 5/5-14/>14):	0/0/100	15/18/67	N/A	N/A
Incidence rate (cases/10,000 population in endemic areas):	0.001	0.28	N/A	N/A
Number of endemic 1 <sup>st</sup> sub-national administrative level divisions:	4	7	N/A	N/A
Population at risk <sup>2</sup> (% # at risk/total population):	100% (8,547,100/8,547,100)	100% (8,547,100/8,547,100)	N/A	N/A
Was there any outbreak?	No	Yes	N/A	N/A
Number of new <sup>3</sup> foci:	0	3	N/A	N/A


N/A = Not applicable; <sup>1</sup> No specific definition of relapse at the national level available; <sup>2</sup> Defined as "Number of people living in 1<sup>st</sup> sub-national administrative level endemic areas"; <sup>3</sup> Defined as "In this reporting period, an area at the first sub-national administrative level reporting cases for the first time ever".

### Monthly distribution of new cases (January-December)


2016	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data
CL	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

#### Visceral leishmaniasis




#### Cutaneous leishmaniasis




### Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2016

#### Visceral leishmaniasis



#### Cutaneous leishmaniasis Imported cases



## Disease distribution of new VL and CL cases at province level per 10,000 population (2016)

### Visceral leishmaniasis




[www.who.int/leishmaniasis/Map-VL-Israel-2016.png](http://www.who.int/leishmaniasis/Map-VL-Israel-2016.png)

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/HTM/NTD/IDM

### Cutaneous leishmaniasis



[www.who.int/leishmaniasis/Map-CL-Israel-2016.png](http://www.who.int/leishmaniasis/Map-CL-Israel-2016.png)

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/HTM/NTD/IDM

## CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available
Type of surveillance:	Integrated
Is there a vector control programme?	No
Type of insecticide used for Indoor residual Spraying (IRS):	N/A <sup>5</sup>
Year latest national guidelines:	2016 <sup>4</sup>
Is leishmaniasis notifiable (mandatory report)?	Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities:	4 HMOs and regional health facilities in endemic areas

<sup>4</sup> A position paper: The aspects of case definition, optimal diagnostic methods and reporting CL

<sup>5</sup> Transmission is zoonotic and organized control activities, when present are being carried out outdoors. Indoor sand fly control is being carried out by the public, using ventilators repellents and vaporizing devices.

## DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	No data	No data	N/A	N/A
Cases diagnosed by RDT* (% , # RDT+/ total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (% , # RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	No data	No data**	N/A	N/A
Proportion of positive slides* (% , # slides + / total slides):	No data	No data	N/A	N/A
Cases diagnosed clinically* (% , # clinical cases/ total cases):	No data	No data**	N/A	N/A
Proportion of CL cases with lesions equal to or greater than 4 cm*:	N/A	No data	N/A	N/A
Proportion of CL cases with 4 or more lesions* (% , # CL cases/ total CL cases):	N/A	No data	N/A	N/A
Percentage of cases with HIV coinfection*:	No data	N/A	No data	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

\* These indicators only apply for new cases; \*\* Several diagnostic methods are available but the proportion of cases confirmed by direct exam (parasitology) was not available

## TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? **No**
- ▶ Antileishmanial medicines included in the National Medicine List: **Liposomal amphotericin B, Miltefosine, Intraleisional sodium; stibogluconate (Pentostam) - for local treatments; Sodium stibogluconate (Pentostam) - for systemic treatments**

### TREATMENT OUTCOME

	VL	CL
Proportion of cases treated* (% , # treated cases/ total cases):	No data	No data
Initial cure rate* (% , # cases initially cured /total cases):	No data	No data
Failure <sup>6</sup> rate* (% , # patients with treatment failure /total cases):	No data	No data
Case fatality rate* (% , # patients who died/ total cases):	No data	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis

\* These indicators only apply for new cases

<sup>6</sup> Failure in this country is defined as: no definition available